Navigation Links
Novartis Drug Diovan Shows Superior Benefits

Results of a Japanese study have given drug giant Novartis AG, more reasons to smile. According to the study published in The Lancet, the company’s blood pressure// drug Diovan was observed to reduce the risks of strokes and cardiovascular events by up to 40 percent.

The study titled the Jikei Heart Study, was based on 3,000 people aged 20 to 79, with high blood pressure, ischemic heart disease or congestive heart failure. The study which was published recently in The Lancet, showed that Diovan produced a 39 percent reduction in cardiovascular events and a 40 percent cut in strokes.

The study compared Diovan when added to a conventional non-angiotensin receptor blocker (ARB) versus the non-ARB therapy alone. Accordingly, the superior benefits reported with Diovan led to an early termination of the study.

In addition to its impact on overall cardiovascular events and stroke, other benefits of Diovan demonstrated were: relative reductions of 65 percent in angina pectoris, 46 percent in heart failure and 81 percent in aortic dissection - separation of the wall layers in the body's main artery – as compared to other treatment groups.

There were few adverse events (2.5 percent overall) with no significant difference in tolerability between the groups. According to investigators, these effects were reported independently of blood pressure reductions.

Says Gordon McInnes, Professor of Medicine at the Western Infirmary in Glasgow, Scotland:"The results of this trial carry an important clinical message for physicians across the globe who are trying to protect patients from debilitating complications such as stroke. "Jikei Heart tells us that adding Diovan to usual treatment regimens can offer substantial long-term protection”, he added.

The Jikei Heart Study is the first controlled trial to assess the cardiovascular benefits of adding the angiotensin receptor blocker, or ARB, Diovan to conventional non-A RB therapy, compared to non-ARB therapy alone- in a large Japanese population. Key events evaluated as part of the primary endpoint included heart attack, stroke and hospitalization for heart failure or angina pectoris.

"Innovative clinical trials have helped Diovan to advance cardiovascular patient care,” Ameet Nathwani, Global Head of Cardiovascular and Metabolic Clinical Research, Development and Medical Affairs, Novartis Pharma AG was quoted. "The results of the independent Jikei Heart Study add to the already large body of evidence demonstrating Diovan's efficacy in lowering blood pressure and preventing cardiovascular events”, he added, welcoming the results.
AN/M
'"/>




Related medicine news :

1. Novartis files application with FDA for Zometa
2. Canine Painkiller unveiled by Novartis
3. Glivec the hot cancer drug from Novartis
4. Zometa [Novartis Drug] For Treatment Of Paget’s Diseas
5. Novartis MS Drug Shows Promising Results
6. Bird-flu Vaccine Adjuvant Contract Goes to Novartis
7. Drop Patent Petition, Activists Ask Novartis
8. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
9. Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board
10. Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors
11. Experimental treatment for Ebola Virus Shows promising results in mice
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Mohebi Hair Restoration, has recently contributed a medical article to the newly revamped ... cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular ...
(Date:10/12/2017)... ... 12, 2017 , ... Health Literacy Innovations (HLI), creator of ... and the Cancer Patient Education Network (CPEN), an independent professional organization that shares ... strategic alliance. , As CPEN’s strategic partner, HLI will help support CPEN ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
Breaking Medicine Technology: